Hudson Bay Capital Management
PTGX icon

Hudson Bay Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Hudson Bay Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$396K Sell
3,760
-105,855
-97% -$9.37M ﹤0.01% 1002
2025
Q4 		$9.57M Buy
+109,615
New +$8.97M 0.03% 355

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Hudson Bay Capital Management's PTGX Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 97% in Q1 2026, selling an estimated $9.37M and leaving 3,760 shares worth $396K. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

Hudson Bay Capital Management first reported a position in PTGX in Q4 2025 and has held it in 2 quarters since. The position peaked at $9.57M in Q4 2025. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Hudson Bay Capital Management held 3,760 shares of Protagonist Therapeutics worth $396K as of Q1 2026.
  • Hudson Bay Capital Management sold 105,855 Protagonist Therapeutics shares in Q1 2026, an estimated $9.37M.
  • Protagonist Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1002 holding.
  • Hudson Bay Capital Management first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Hudson Bay Capital Management's Protagonist Therapeutics position peaked at $9.57M in Q4 2025.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.